Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

4 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

7(77.8%)

Phase 1

2(22.2%)

9Total

Phase 2(7)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05600686Phase 2Recruiting

Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma

Role: lead

NCT06905509Phase 2Recruiting

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Role: lead

NCT06854159Phase 2Recruiting

Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy

Role: lead

NCT04587687Phase 2Recruiting

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Role: lead

NCT04578600Phase 1Completed

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Role: lead

NCT02542657Phase 1Active Not Recruiting

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

Role: lead

NCT01811368Phase 2Unknown

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Role: lead

NCT01716208Phase 2Completed

Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma

Role: lead

NCT01736943Phase 2Completed

Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

Role: lead

All 9 trials loaded